Thatโs the slogan of a new Harvard University spinout that plans to put millions behind a hotly disputed rejuvenation discovery.
The startup, Elevian, which is based in San Francisco, says it intends to explore whether daily injections of a protein called GDF11 can promote โthe bodyโs ability to restore itselfโ and eventually treat conditions including coronary artery disease, Alzheimerโs, and the muscle-loss condition sarcopenia.